MedTrace Logo

Study of SGR-1505 in Mature B-Cell Neoplasms

NCT05544019 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2026-02-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

Conditions

  • Mature B-Cell Neoplasm
  • Non Hodgkin Lymphoma
  • DLBCL
  • Waldenstrom Macroglobulinemia
  • MALT Lymphoma
  • Follicular Lymphoma
  • Pediatric-Type Follicular Lymphoma
  • IRF4 Gene Rearrangement
  • EBV-Positive DLBCL, Nos
  • Burkitt Lymphoma
  • Plasmablastic Lymphoma
  • High-grade B-cell Lymphoma
  • Primary Cutaneous Follicle Center Lymphoma
  • Primary Effusion Lymphoma
  • Mantle Cell Lymphoma
  • DLBCL Germinal Center B-Cell Type
  • Primary Mediastinal Large B Cell Lymphoma
  • T-Cell/Histiocyte Rich Lymphoma
  • ALK-Positive Large B-Cell Lymphoma
  • Primary Cutaneous Diffuse Large B-Cell Lymphoma
  • Splenic Marginal Zone Lymphoma
  • Chronic Lymphocytic Leukemia
  • Nodal Marginal Zone Lymphoma
  • HHV8-Positive DLBCL, Nos
  • Lymphoplasmacytic Lymphoma
  • Duodenal-Type Follicular Lymphoma

Interventions

DRUG

SGR-1505

SGR-1505 will be administered orally.

Sponsors & Collaborators

  • Schrödinger, Inc.

    lead INDUSTRY

Principal Investigators

  • Frank G Basile, M.D. · Schrodinger Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-10
Primary Completion
2027-11-30
Completion
2027-11-30
FDA Drug
Yes

Countries

  • United States
  • France
  • Italy
  • Moldova
  • Poland
  • Romania
  • Spain
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05544019 on ClinicalTrials.gov